Double-blind placebo controlled study of the adjunctive effect of tropisetron on cognitive deficits in schizophrenia

Double-blind placebo controlled study of the adjunctive effect of tropisetron on cognitive deficits in schizophrenia - Double-blind placebo controlled study of the adjunctive effect of tropisetron on cognitive deficits in schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003084

Enrollment

Registered

2010-01-25

Start date

2006-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

10mg of tropisetron daily during 8 weeks placebo during 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: outpatient of Chiba University Hospital with schizophrenia meeting the DSM-IV-TR criteria taking risperidone (2-6 mg/day) for at least 8 weeks

Exclusion criteria

Exclusion criteria: history of other neurologic illness, pregnant or suckling are excluded

Design outcomes

Primary

Measure	Time frame
cognitive function of the patient at 4, and 8 weeks after starting	—

Secondary

Measure	Time frame
mental status, quality of life, and so on of the patient at 4, and 8 weeks after starting	—

Countries

Japan

Contacts

Public ContactAkihiro Shiina

Chiba University Hospital Department of Psychiatry

shiina-akihiro@faculty.chiba-u.jp+81-43-226-2297

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026